Treatment patterns and costs among US patients with DLBCL not treated with 2L stem cell transplantation - supplementary material.docx

Supplementary Table 1. 1L treatment
Supplementary Table 2. 2L treatment
Supplementary Table 4. 4L treatment
Supplementary Table 5. Medical and pharmacy costs during the post-index period for all patients (PPPY)
Supplementary Figure 1. Start of 2L therapy (index) by year for all patients (N = 750)
Supplementary Figure 2. Prevalence (A) and mean number (B) of outpatient visits (PPPY)
Supplementary Figure 3. Inpatient hospitalizations (A) prevalence, (B) mean length of inpatient stay (PPPY), and (C) mean number of inpatient visits (PPPY)
Supplementary Figure 4. Emergency department visits (A) prevalence and (B) mean number of emergency department visits (PPPY)